245 related articles for article (PubMed ID: 29192323)
61. Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
El Hachem M; Gesualdo F; Diociaiuti A; Berti I; Vercellino N; Boccaletti V; Neri I; Porcedda G; Greco A; Carnevale C; Oranges T; Cutrone M; Dalmonte P
Ital J Pediatr; 2017 Apr; 43(1):40. PubMed ID: 28424095
[TBL] [Abstract][Full Text] [Related]
62. [Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice].
Shuming C; Shaoquan C; Zaizhong Z; Chengjin L; Yin X; Chen L; Qingjin H; Lie W
Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Nov; 31(6):446-50. PubMed ID: 27055325
[TBL] [Abstract][Full Text] [Related]
63. [Infantile hemangioma and propranolol: a therapeutic "revolution". Literature review].
Yilmaz L; Dangoisse C; Semaille P
Rev Med Brux; 2013; 34(6):479-84. PubMed ID: 24505868
[TBL] [Abstract][Full Text] [Related]
64. The expression and role of glycolysis-associated molecules in infantile hemangioma.
Chen J; Wu D; Dong Z; Chen A; Liu S
Life Sci; 2020 Oct; 259():118215. PubMed ID: 32768579
[TBL] [Abstract][Full Text] [Related]
65. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
Storch CH; Hoeger PH
Br J Dermatol; 2010 Aug; 163(2):269-74. PubMed ID: 20456345
[TBL] [Abstract][Full Text] [Related]
66. A randomized, controlled trial of oral propranolol in infantile hemangioma.
Léauté-Labrèze C; Hoeger P; Mazereeuw-Hautier J; Guibaud L; Baselga E; Posiunas G; Phillips RJ; Caceres H; Lopez Gutierrez JC; Ballona R; Friedlander SF; Powell J; Perek D; Metz B; Barbarot S; Maruani A; Szalai ZZ; Krol A; Boccara O; Foelster-Holst R; Febrer Bosch MI; Su J; Buckova H; Torrelo A; Cambazard F; Grantzow R; Wargon O; Wyrzykowski D; Roessler J; Bernabeu-Wittel J; Valencia AM; Przewratil P; Glick S; Pope E; Birchall N; Benjamin L; Mancini AJ; Vabres P; Souteyrand P; Frieden IJ; Berul CI; Mehta CR; Prey S; Boralevi F; Morgan CC; Heritier S; Delarue A; Voisard JJ
N Engl J Med; 2015 Feb; 372(8):735-46. PubMed ID: 25693013
[TBL] [Abstract][Full Text] [Related]
67. The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres.
Lochmann A; Nitzsche H; von Einem S; Schwarz E; Mäder K
J Control Release; 2010 Oct; 147(1):92-100. PubMed ID: 20603166
[TBL] [Abstract][Full Text] [Related]
68. Hemangioma Endothelial Cells and Hemangioma Stem Cells in Infantile Hemangioma.
Sun Y; Qiu F; Hu C; Guo Y; Lei S
Ann Plast Surg; 2022 Feb; 88(2):244-249. PubMed ID: 35023872
[TBL] [Abstract][Full Text] [Related]
69. Treatment of infantile hemangiomas with beta-blockers: a review.
Shah S; Frieden IJ
Skin Therapy Lett; 2013; 18(6):5-7. PubMed ID: 24305730
[TBL] [Abstract][Full Text] [Related]
70. Study on the Mechanism of Targeted Poly(lactic-coglycolic acid) Nano-Delivery Carriers in the Treatment of Hemangiomas.
Liao S; Wu J; Li Z; Cheng G; Lu B; Liu G; Li X; Lu W
J Nanosci Nanotechnol; 2021 Feb; 21(2):1236-1243. PubMed ID: 33183467
[TBL] [Abstract][Full Text] [Related]
71. When to stop propranolol for infantile hemangioma.
Chang L; Gu Y; Yu Z; Ying H; Qiu Y; Ma G; Chen H; Jin Y; Lin X
Sci Rep; 2017 Feb; 7():43292. PubMed ID: 28225076
[TBL] [Abstract][Full Text] [Related]
72. Late rebound of infantile hemangioma after cessation of oral propranolol.
Shehata N; Powell J; Dubois J; Hatami A; Rousseau E; Ondrejchak S; McCuaig C
Pediatr Dermatol; 2013; 30(5):587-91. PubMed ID: 24016283
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma.
Aydin Köker S; Kömüroğlu AU; Köksoy AY; Şiraz ÜG; Tekin E; Köker A
Arch Pediatr; 2021 May; 28(4):296-300. PubMed ID: 33715934
[TBL] [Abstract][Full Text] [Related]
74. Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma.
Wang L; Zheng K; Li X; Wang Y; Xu Q
Biomed Res Int; 2020; 2020():8732871. PubMed ID: 32219146
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
Sagi L; Zvulunov A; Lapidoth M; Ben Amitai D
Dermatology; 2014; 228(2):136-44. PubMed ID: 24556822
[TBL] [Abstract][Full Text] [Related]
76. [The advance of β-blockers in the treatment of infantile hemangiomas].
Lin TT; He YJ
Zhonghua Yan Ke Za Zhi; 2013 Dec; 49(12):1138-44. PubMed ID: 24499701
[TBL] [Abstract][Full Text] [Related]
77. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
Chim H; Armijo BS; Miller E; Gliniak C; Serret MA; Gosain AK
Ann Surg; 2012 Jul; 256(1):146-56. PubMed ID: 22580939
[TBL] [Abstract][Full Text] [Related]
78. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.
Sondhi V; Patnaik SK
J Pediatr Hematol Oncol; 2013 Oct; 35(7):493-9. PubMed ID: 23929318
[TBL] [Abstract][Full Text] [Related]
79. Repair effect of diabetic ulcers with recombinant human epidermal growth factor loaded by sustained-release microspheres.
Dong X; Xu J; Wang W; Luo H; Liang X; Zhang L; Wang H; Wang P; Chang J
Sci China C Life Sci; 2008 Nov; 51(11):1039-44. PubMed ID: 18989647
[TBL] [Abstract][Full Text] [Related]
80. Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.
Zhang W; Chen G; Wang FQ; Ren JG; Zhu JY; Cai Y; Zhao JH; Jia J; Zhao YF
J Invest Dermatol; 2015 Dec; 135(12):3163-3172. PubMed ID: 26288359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
